Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Research Article Volume 6 Issue 3

Post-vaccination Comparative Studies of the Dynamics of Antibodies Neutralizing the SARS-CoV-2 Virus During Vaccination with Various Vaccines in Kazakhstan

JM Bekshin1, M Rysuly2, AT Abishev3, GK Akhmetova4 and AS Sadvakas5*

1Head of the Department of Sanitary and Epidemiological Control for the City of Almaty, Kazakhstan

2Researcher, Kazakh National Center for Dermatovenereology and Infectious Diseases of the Ministry of Health, Almaty, Kazakhstan

3Kazakh National Center for Dermatovenereology and Infectious Diseases of the Ministry of Health, Almaty

4Head of the Department of Clinical Trials of the Scientific Center for Anti-Infectious Drugs, Almaty, Kazakhstan

5Assistant of the Department of Clinical Laboratory Diagnostics, Asfendiyarov Kazakh National Medical University, Kazakhstan

*Corresponding Author: AS Sadvakas, Assistant of the Department of Clinical Laboratory Diagnostics, Asfendiyarov Kazakh National Medical University, Kazakhstan.

Received: February 09, 2023; Published: February 22, 2023

Abstract

Post-vaccination measurement of the level of antibodies neutralizing the SARS-CoV-2 virus (NA) in blood serum is a marker for monitoring the effectiveness of immunity formation [1,2]. In 4 groups of 462 patients, a comparative study of the neutralizing effectiveness of antibodies was carried out with single and double administration of CoronaVac brand vaccines (SynoVac), VeroCell (Sinofarm), Sputnik-V (GamCovidVac) and domestically produced QazVac (QazCovid-in). Of the 462 vaccinated subjects examined for NA, 46 recovered from COVID-19 and 416 were not infected with the SARS CoV-2 virus. The latter were included in the present study. In 34 (8.2%) patients, threshold values of NA were not found in the blood serum after vaccination. The Chinese-made vaccines Vero-Cell and the Kazakhstani manufacturer QazCovid (Research Institute for Biological Safety of the Ministry of Education and Science of the Republic of Kazakhstan) had practically the same indicators of post-vaccination immunogenicity.

Keywords: Vaccines; CoronaVac (SynoVac); VeroCell (Sinofarm); Sputnik-V (GamCovidVac); QazVac (QazCovid-in); SARS-CoV-2 IgG Neutralizing Antibodies; Quantitatively; Coronavirus-19

References

  1. Evaluation of COVID-19 vaccine effectiveness. WHO, Interim Guidance. 17 March (2021): 60.
  2. Plotkin SA and Gilbert PB. “Nomenclature for immune correlates of protection after vaccination”. Clinical Infectious Diseases 54.11 (2012): 1615-1617.
  3. Fei Xiang., et al. “Antibody Detection and Dynamic Characteristics in Patients with COVID-19”. Clinical Infectious Diseases, ciaa461.
  4. Takahashi T and Iwasaki A. “Sex differences in immune responses”. Science 6527 (2021): 347-348.
  5. Thailand Food and Drug Administration. Summary of Product Characteristic CoronaVac (2021).
  6. Zhang Y., et al. “Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial”. Lancet Infectious Diseases 2 (2021): 181-192.
  7. Voysey M., et al. “Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK”. Lancet 10269 (2021): 99-111.
  8. Thompson MG., et al. “Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. The New England Journal of Medicine 4 (2021): 320-329.
  9. Al Kaabi N., et al. “Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial”. JAMA 1 (2021): 32635-32645.
  10. Yan ZP., et al. “COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials”. Pharmaceuticals (Basel)5 (2021): 406.
  11. Madhi SA., et al. “Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant”. The New England Journal of Medicine 20 (2021): 1885-1898.
  12. Pan H., et al. “Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial”. medRxiv (2021).
  13. Sterlin D., et al. “IgA dominates the early neutralizing antibody response to SARS-CoV-2”. Science Translational Medicine 577 (2021).
  14. Madhi SA., et al. “Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant”. The New England Journal of Medicine (2021).
  15. Rossman H., et al. “COVID-19 dynamics after a national immunization program in Israel”. Nature Medicine (2021).
  16. Dejnirattisai W., et al. “Antibody evasion by the P.1 strain of SARS-CoV-2”. Cell (2021).
  17. Yuan M., et al. “Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies”. Biochemical and Biophysical Research Communications 538 (2021): 192-203.
  18. Greaney AJ., et al. “The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD”. bioRxiv (2021).
  19. Abu-Raddad LJ., et al. “Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses”. Journal of Travel Medicine (2021).
  20. Earle KA., et al. “Evidence for antibody as a protective correlate for COVID-19 vaccines”. medRxiv (2021): 03.17.20200246.
  21. Khoury DS., et al. “Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection”. Nature Medicine (2021).
  22. Craig Fenwickhttps., et al. “Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies”. Journal of Virology3 (2021): e01828-20.
  23. Zhao J., et al. “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”. Clinical Infectious Diseases (2019).

Citation

Citation: AS Sadvakas., et al. “Post-vaccination Comparative Studies of the Dynamics of Antibodies Neutralizing the SARS-CoV-2 Virus During Vaccination with Various Vaccines in Kazakhstan". Acta Scientific Gastrointestinal Disorders 6.3 (2023): 21-30.

Copyright

Copyright: © 2022 AS Sadvakas., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In




News and Events


Contact US